✦ LIBER ✦

AGE BIAS IN CLINICAL TRIALS OF PARKINSON'S DISEASE TREATMENT

✍ Scribed by Anoja Rajapakse; Senaka Rajapakse; Jeremy Playfer

Book ID: 109130334
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 56 KB
Volume: 56
Category: Article
ISSN: 0002-8614
DOI: 10.1111/j.1532-5415.2008.02024.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neuroprotection in Parkinson's disease:

Neuroprotection in Parkinson's disease: Clinical trials

✍ Fabrizio Stocchi; C. Warren Olanow 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 2 views

Impact of placebo assignment in clinical

Impact of placebo assignment in clinical trials of Parkinson's disease

✍ Christopher G. Goetz; Kimberly Janko; Lucy Blasucci; Jean A. Jaglin 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 1 views

## Abstract Informed consent procedures in placebo‐controlled trials are developed to ensure that subjects entering studies clearly understand the possibility of placebo assignment. The extent of patient understanding and the impact of learning that they were assigned placebo treatment have not bee

A comparison of treatment thresholds in

A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts

✍ Connie Marras; Anthony E. Lang; Shirley W. Eberly; David Oakes; Stanley Fahn; St 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

## Abstract Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) and Parkinson Research Examination of CEP‐1347 Trial (PRECEPT) were two clinical trials of potential disease‐modifying agents for Parkinson's disease that used the time to reaching disability sufficient to require d

Selection bias and treatment heterogenei

Selection bias and treatment heterogeneity in clinical trials

✍ Nicholas T. Longford 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

A common perception about many commercially available medical treatments is that they are e!ective for every patient having the relevant indication and that developers have provided the regulatory authorities with evidence of such a property. We show that the standard of evidence is much lower and t

Using global statistical tests in long-t

Using global statistical tests in long-term Parkinson's disease clinical trials

✍ Peng Huang; Christopher G. Goetz; Robert F. Woolson; Barbara Tilley; Douglas Ker 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB

## Abstract Parkinson's disease (PD) impairments are multidimensional, making it difficult to choose a single primary outcome when evaluating treatments to stop or lessen the long‐term decline in PD. We review commonly used multivariate statistical methods for assessing a treatment's global impact,

Has “levodopa-induced neuropathy” been r

Has “levodopa-induced neuropathy” been reported in Parkinson's disease clinical trials?

✍ Tiago Teodoro; Daniela Pires; Mário M. Rosa; Miguel Coelho; Cristina Sampaio; Jo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 573 KB

The disorders of voice and speech in Parkinson's disease (PD) result from involvements in several subsystems including respiration, phonation, articulation, and prosody. [1][2][3] We investigated the feasibility of acoustic measures for the identification of voice and speech disorders in PD, using a